Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Consistent with this notion, the survivin siRNA approach was used throughout the history of survivin studies [ 114 – 118 ]; the survivin siRNA studies in recent years show a clear trend of developing and using various new delivery technologies of survivin siRNA with or without combination of a cancer drug for therapeutics in vitro [ 119 – 123 ] and in vivo [ 124 – 131 ].

also in 19,460 other papers